Predicting STAT1 As a Prognostic Marker in Patients with Solid Cancer

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2020 May 20

PMID 32426049

Citations 23

Authors

Jinguo Zhang

Fanchen Wang

Fangran Liu

Guoxiong Xu

Affiliations

Soon will be listed here.

Abstract

Background: Aberrant activities of signal transducer and activator of transcription 1 (STAT1) have been implicated in cancer development. However, the prognostic value of STAT1 remains unclear. This report identified the role of STAT1 in prognosis in patients with solid cancer through open literature and The Cancer Genome Atlas (TCGA) database.

Methods: Published articles were obtained from PubMed, Web of Science, and Embase databases according to a search strategy up to October 2019. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were extracted to assess the prognostic factors of patients. TCGA datasets were used to explore the prognostic value of STAT1 in various cancers.

Results: A total of 15 studies incorporating 2839 patients with solid cancers were included. Pooled data showed that overexpressed STAT1 favored long overall survival (OS) (HR = 0.604, 95% CI = 0.431-0.846, = 0.003) and disease-specific survival (DSS) (HR = 0.650, 95% CI = 0.512-0.825, = 0.000). In subgroup analyses, highly expressed STAT1 was correlated with long OS of patients with high-grade serous ovarian cancer and oral squamous cell carcinoma. Data extracted from TCGA datasets unveiled that STAT1 expression was significantly higher in 12 cancers (e.g. bladder and breast) than their adjacent normal tissues. Again, highly expressed STAT1 favored long OS of patients with ovarian cancer as well as rectum adenocarcinoma, sarcoma, and skin cutaneous melanoma. However, in renal carcinoma, brain lower grade glioma, lung adenocarcinoma, and pancreatic cancer, highly expressed STAT1 was correlated with poor OS of patients. Particularly in renal carcinoma, increased STAT1 expression was associated with high grade, later stage, large tumor size, and lymph node and distant metastasis.

Conclusion: STAT1 has been identified to have prognostic value in patients with solid cancer. Highly expressed STAT1 may predict prognosis in cancer patients based on their tumor types.

Citing Articles

STAT1 and STAT4 expression as prognostic biomarkers in patients with bladder cancer.

El Ahanidi H, El Azzouzi M, Addoum B, Tetou M, Hassan I, Al Bouzidi A Mol Clin Oncol. 2025; 22(4):33.

PMID: 39989605 PMC: 11843079. DOI: 10.3892/mco.2025.2828.

Metastatic melanoma: An integrated analysis to identify critical regulators associated with prognosis, pathogenesis and targeted therapies.

Chaharlashkar Z, Saeedi Honar Y, Abdollahpour-Alitappeh M, Parvizpour S, Barzegar A, Alizadeh E PLoS One. 2025; 20(1):e0312754.

PMID: 39820173 PMC: 11737774. DOI: 10.1371/journal.pone.0312754.

Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Arising From Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Ziaziaris W, Lim C, Sioson L, Gill A, Samra J, Sahni S Cancer Med. 2024; 13(23):e70499.

PMID: 39660530 PMC: 11632396. DOI: 10.1002/cam4.70499.

Curcumin: A Potential Weapon in the Prevention and Treatment of Head and Neck Cancer.

Vesela K, Kejik Z, Masarik M, Babula P, Dytrych P, Martasek P ACS Pharmacol Transl Sci. 2024; 7(11):3394-3418.

PMID: 39539276 PMC: 11555516. DOI: 10.1021/acsptsci.4c00518.

Comprehensive exploration of immune checkpoint-related genes in the prognosis and tumor immune microenvironment of pancreatic adenocarcinoma.

Chen X, Zhang H Clinics (Sao Paulo). 2024; 79:100481.

PMID: 39208654 PMC: 11399560. DOI: 10.1016/j.clinsp.2024.100481.

References

Xu X, Fu X, Plate J, Chong A . IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res. 1998; 58(13):2832-7. View

Arumuggam N, Bhowmick N, Rupasinghe H . A Review: Phytochemicals Targeting JAK/STAT Signaling and IDO Expression in Cancer. Phytother Res. 2015; 29(6):805-17. DOI: 10.1002/ptr.5327. View

Tymoszuk P, Charoentong P, Hackl H, Spilka R, Muller-Holzner E, Trajanoski Z . High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer. BMC Cancer. 2014; 14:257. PMC: 4021106. DOI: 10.1186/1471-2407-14-257. View

Kaida H, Azuma K, Kawahara A, Sadashima E, Hattori S, Takamori S . The assessment of correlation and prognosis among F-FDG uptake parameters, Glut1, pStat1 and pStat3 in surgically resected non-small cell lung cancer patients. Oncotarget. 2018; 9(62):31971-31984. PMC: 6112832. DOI: 10.18632/oncotarget.25865. View

Hannesdottir L, Daschil N, Philipp S, Tymoszuk P, Muller-Holzner E, Klima G . MMTV-neu mice deficient in STAT1 are susceptible to develop ovarian teratomas. Int J Dev Biol. 2012; 56(4):279-83. DOI: 10.1387/ijdb.113397lh. View

Huang S, Bucana C, Van Arsdall M, Fidler I . Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene. 2002; 21(16):2504-12. DOI: 10.1038/sj.onc.1205341. View

Wang Y, Song X, Zheng Y, Liu Z, Li Y, Qian X . Cancer/testis Antigen MAGEA3 Interacts with STAT1 and Remodels the Tumor Microenvironment. Int J Med Sci. 2018; 15(14):1702-1712. PMC: 6299422. DOI: 10.7150/ijms.27643. View

Chen J, Liu X, Jiao H, Peng L, Huo Z, Yang W . Prognostic and clinical significance of STAT3 and MMP9 in patients with gastric cancer: a meta-analysis of a Chinese cohort. Int J Clin Exp Med. 2015; 8(1):546-57. PMC: 4358484. View

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6(7):e1000100. PMC: 2707010. DOI: 10.1371/journal.pmed.1000100. View

10.

Baran-Marszak F, Feuillard J, Najjar I, Le Clorennec C, Bechet J, Dusanter-Fourt I . Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells. Blood. 2004; 104(8):2475-83. DOI: 10.1182/blood-2003-10-3508. View

11.

Arzt L, Kothmaier H, Halbwedl I, Quehenberger F, Popper H . Signal transducer and activator of transcription 1 (STAT1) acts like an oncogene in malignant pleural mesothelioma. Virchows Arch. 2014; 465(1):79-88. DOI: 10.1007/s00428-014-1584-8. View

12.

Zhang Y, Jin G, Zhang J, Mi R, Zhou Y, Fan W . Overexpression of STAT1 suppresses angiogenesis under hypoxia by regulating VEGF‑A in human glioma cells. Biomed Pharmacother. 2018; 104:566-575. DOI: 10.1016/j.biopha.2018.05.079. View

13.

Ryan N, Anderson K, Volpedo G, Hamza O, Varikuti S, Satoskar A . STAT1 inhibits T-cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma. Int J Cancer. 2019; 146(6):1717-1729. PMC: 7366342. DOI: 10.1002/ijc.32781. View

14.

DerSimonian R, Kacker R . Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2006; 28(2):105-14. DOI: 10.1016/j.cct.2006.04.004. View

15.

Gujam F, McMillan D, Edwards J . The relationship between total and phosphorylated STAT1 and STAT3 tumour cell expression, components of tumour microenvironment and survival in patients with invasive ductal breast cancer. Oncotarget. 2016; 7(47):77607-77621. PMC: 5363608. DOI: 10.18632/oncotarget.12730. View

16.

Zhang X, Li X, Tan F, Yu N, Pei H . STAT1 Inhibits MiR-181a Expression to Suppress Colorectal Cancer Cell Proliferation Through PTEN/Akt. J Cell Biochem. 2017; 118(10):3435-3443. DOI: 10.1002/jcb.26000. View

17.

Pencik J, Pham H, Schmoellerl J, Javaheri T, Schlederer M, Culig Z . JAK-STAT signaling in cancer: From cytokines to non-coding genome. Cytokine. 2016; 87:26-36. PMC: 6059362. DOI: 10.1016/j.cyto.2016.06.017. View

18.

Magkou C, Giannopoulou I, Theohari I, Fytou A, Rafailidis P, Nomikos A . Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer. Histopathology. 2012; 60(7):1125-32. DOI: 10.1111/j.1365-2559.2011.04143.x. View

19.

Chen H, Chou C, Wu Y, Hsueh W, Hsu C, Guo H . Constitutive STAT5 activation correlates with better survival in cervical cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2011; 82(2):658-66. DOI: 10.1016/j.ijrobp.2010.11.043. View

20.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View